February 27, 2018 / 11:16 PM / 4 months ago

BRIEF-Horizon Pharma PLC Submits Supplemental NDA For Ravicti

Feb 27 (Reuters) - Horizon Pharma Plc:

* HORIZON PHARMA PLC SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR RAVICTI® (GLYCEROL PHENYLBUTYRATE) ORAL LIQUID TO EXPAND AGE RANGE TO INCLUDE NEWBORNS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below